Tilray (TLRY.US), a pharmaceutical and cannabis company, gained roughly 20% in pre-market trading as the firm announced it has entered into an agreement with Grow Pharma - the leader in supplying unlicensed cannabis medicines in the UK. Under the agreement, Grow Pharma will distribute Tilray’s medical cannabis products across the United Kingdom. Tilray’s stock price skyrocketed in recent weeks, which might be associated with hopes that Joe Biden could potentially introduce federal marijuana legalisation.

Tilray (TLRY.US) gained in recent weeks as Biden is expected to support medical cannabis legalisation. Stock price climbed above key area at $22.45 and is expected to open almost 20% higher today. Source: xStation5
DAX: DE40 tries to hold the momentum 📈Brenntag and ArcelorMittal under pressure
Delta Airlines stock lifts off after earnings✈️
Stock of the Week - Super Micro Computer (09.10.2025)
US OPEN: Pepsico and Delta reporting, S&P500 hanging on the top ↔️